Abstract
Background: Glutaryl melatonin, which is synthesized from melatonin and is a pineal glandderived neurohormone with anti-inflammatory and anti-oxidant properties, was comparatively investigated for its potential use as a topical anti-inflammatory agent.
Objective: Glutaryl melatonin, synthesized and screened for in vitro anti-candidiasis and in vitro and in vivo anti-inflammatory activities, was formulated as a niosome gel for topical oral evaluation in 5- fluorouracil-induced oral mucositis in mice.
Methods: In vitro anti-fungal activity in Candida albicans, in vitro anti-inflammatory activity in Escherichia coli liposaccharide-induced RAW cells and in vivo anti-inflammatory activity using a croton oilinduced ear edema model in ICR mice were investigated. Mucositis in mice (n= 6/group, 10-week-old mice) was induced by intraperitoneal injections of 5-fluorouracil, and the mice were subjected to a topical oral application of niosome gel containing melatonin (2% w/w) or glutaryl melatonin (2% w/w) and were compared with mice subjected to blank, fluocinolone acetonide (0.5% w/w) and control conditions.
Results: Glutaryl melatonin, at a 14.2 mM concentration, showed the highest fungicidal effect on C. albicans using the broth dilution method, indicating a nonsignificant difference from 1 μM of nystatin (p = 0.05). Nitric oxide, interleukin-6 and tumor necrosis factors were analyzed by ELISA. Liposaccharide-induced RAW cells were significantly reduced by glutaryl melatonin (p < 0.01). Ear edema inhibition of glutaryl melatonin was significant 1 h after application compared with that of melatonin (p = 0.03). Food consumption and body weight of the 5-fluorouracil-treated mice were significantly lower than those of the normal mice before all treatments (p < 0.05). Differences in the amount of licking behavior, which were observed in the control group for 5 min, were noticeable in the 5- fluorouracil-treated mice but not in the mice treated with the glutaryl melatonin niosome gel.
Conclusion: Glutaryl melatonin exhibited mild anti-candidiasis and anti-inflammatory properties. The incorporation of glutaryl melatonin in a niosome gel formulation, demonstrated the potential for topical oral applications to reduce oral discomfort caused by 5-fluorouracil treatment in mice.
Keywords: Glutaryl melatonin, anti-candidiasis, anti-inflammation, niosome gel, 5-fluorouracil, injections.
Graphical Abstract
[http://dx.doi.org/10.1007/s00520-010-0892-z] [PMID: 20449755]
[PMID: 23705242]
[http://dx.doi.org/10.1210/edrv-12-2-151] [PMID: 1649044]
[http://dx.doi.org/10.1111/j.1600-079X.1993.tb00478.x] [PMID: 8483103]
[http://dx.doi.org/10.1007/s10620-010-1364-5] [PMID: 20676767]
[http://dx.doi.org/10.1111/j.1600-079X.2012.01014.x] [PMID: 22725668]
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb05402.x] [PMID: 11268363]
[http://dx.doi.org/10.1111/j.1365-2826.2003.01103.x] [PMID: 14636172]
[http://dx.doi.org/10.1016/S0531-5565(01)00209-1] [PMID: 11772529]
[http://dx.doi.org/10.1007/s00360-004-0429-1] [PMID: 15148621]
[http://dx.doi.org/10.1111/jre.12176] [PMID: 24665831]
[PMID: 3155649]
[http://dx.doi.org/10.1002/cncr.20162] [PMID: 15108222]
[http://dx.doi.org/10.3389/fonc.2017.00089] [PMID: 28589080]
[http://dx.doi.org/10.1177/154411130201300405] [PMID: 12191961]
[http://dx.doi.org/10.1016/j.cden.2014.01.001] [PMID: 24655524]
[http://dx.doi.org/10.2334/josnusd.50.377] [PMID: 19106464]
[http://dx.doi.org/10.1016/j.tripleo.2006.10.024] [PMID: 17261374]
[http://dx.doi.org/10.1111/adj.12283] [PMID: 25762041]
[http://dx.doi.org/10.1111/j.1600-079X.2007.00516.x] [PMID: 18289175]
[http://dx.doi.org/10.1016/j.kjms.2016.06.005] [PMID: 27523451]
[http://dx.doi.org/10.1111/j.1365-2621.1976.tb00646.x]
[http://dx.doi.org/10.1007/s11095-006-9032-3] [PMID: 16832611]
[http://dx.doi.org/10.1016/j.archoralbio.2017.02.022] [PMID: 28292674]
[http://dx.doi.org/10.1002/ddr.21177] [PMID: 24826922]
[http://dx.doi.org/10.1007/s10156-013-0639-0] [PMID: 23807392]
[http://dx.doi.org/10.1016/S1773-2247(14)50025-1]
[http://dx.doi.org/10.4155/tde-2018-0001] [PMID: 29681235]
[http://dx.doi.org/10.1016/S0031-9384(98)00014-6] [PMID: 9661982]
[http://dx.doi.org/10.1523/JNEUROSCI.1107-15.2016] [PMID: 27013685]
[http://dx.doi.org/10.1007/BF01067692] [PMID: 4715987]
[PMID: 27533940]
[http://dx.doi.org/10.1016/j.carbpol.2017.02.097] [PMID: 28385220]
[http://dx.doi.org/10.1016/j.carbpol.2011.07.054]
[http://dx.doi.org/10.4314/bcse.v28i1.15]
[http://dx.doi.org/10.1016/j.exer.2012.11.007] [PMID: 23201027]
[http://dx.doi.org/10.1016/j.taap.2015.02.006] [PMID: 25689174]
[http://dx.doi.org/10.1016/j.bbr.2007.07.003] [PMID: 17681386]
[http://dx.doi.org/10.1371/journal.pone.0115686] [PMID: 25671635]
[http://dx.doi.org/10.1208/s12249-018-0966-7] [PMID: 29532424]